secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001601830-24-000018
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports Q4 net loss of $93M, cash $391.6M; '24 clinical data readouts planned
--------------------------------------------------------------------------------

- Net loss $93M in Q4 2023 vs $57.5M a year ago; full-year loss $328.1M vs $239.5M.
- Cash and equivalents $391.6M at Dec 31, 2023, down from $549.9M a year earlier.
- R&D expenses rose to $69.5M in Q4 from $44M; operating cash burn $287.8M for 2023.
- Key clinical milestones: REC-994 Phase 2 data Q3 2024; REC-2282 data Q4 2024; REC-3964 Phase 2 start in 2024.
- Named Kristen Rushton as Chief Business Operations Officer; in-licenced Bayer fibrosis program (Target Epsilon) entering IND-enabling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/0001601830-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/rxrx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer